Viking Therapeutics (NASDAQ:VKTX - Get Free Report) was upgraded by investment analysts at Cantor Fitzgerald to a "strong-buy" rating in a report released on Tuesday,Zacks.com reports.
Several other analysts have also recently issued reports on VKTX. Morgan Stanley reduced their price target on shares of Viking Therapeutics from $105.00 to $102.00 and set an "overweight" rating on the stock in a research report on Thursday, April 24th. Citigroup started coverage on shares of Viking Therapeutics in a report on Friday, February 7th. They set a "neutral" rating and a $38.00 target price on the stock. Piper Sandler dropped their price target on shares of Viking Therapeutics from $74.00 to $71.00 and set an "overweight" rating for the company in a research note on Thursday, February 6th. Raymond James increased their price objective on Viking Therapeutics from $122.00 to $125.00 and gave the company a "strong-buy" rating in a research note on Thursday, February 6th. Finally, Truist Financial reissued a "buy" rating and set a $75.00 target price (down from $95.00) on shares of Viking Therapeutics in a research note on Monday. One investment analyst has rated the stock with a sell rating, two have given a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $87.15.
Get Our Latest Analysis on VKTX
Viking Therapeutics Stock Performance
Viking Therapeutics stock opened at $27.94 on Tuesday. The company has a market capitalization of $3.14 billion, a PE ratio of -27.94 and a beta of 0.84. Viking Therapeutics has a fifty-two week low of $18.92 and a fifty-two week high of $81.86. The firm has a 50 day moving average price of $26.27 and a 200 day moving average price of $39.98.
Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.10). During the same quarter in the previous year, the firm posted ($0.26) earnings per share. The business's quarterly revenue was up .0% compared to the same quarter last year. As a group, equities research analysts forecast that Viking Therapeutics will post -1.56 earnings per share for the current year.
Insider Activity at Viking Therapeutics
In related news, Director Sarah Kathryn Rouan acquired 1,240 shares of the firm's stock in a transaction on Monday, March 31st. The stock was bought at an average price of $24.15 per share, for a total transaction of $29,946.00. Following the completion of the purchase, the director now directly owns 1,240 shares of the company's stock, valued at approximately $29,946. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 4.10% of the company's stock.
Institutional Trading of Viking Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the company. Blue Trust Inc. increased its position in Viking Therapeutics by 75.9% during the fourth quarter. Blue Trust Inc. now owns 716 shares of the biotechnology company's stock worth $29,000 after buying an additional 309 shares during the period. YANKCOM Partnership acquired a new position in shares of Viking Therapeutics in the 4th quarter valued at $33,000. FIL Ltd raised its position in Viking Therapeutics by 116.8% in the 4th quarter. FIL Ltd now owns 1,203 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 648 shares during the last quarter. CIBC Private Wealth Group LLC boosted its stake in Viking Therapeutics by 170.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 1,351 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 851 shares during the period. Finally, Parallel Advisors LLC grew its position in Viking Therapeutics by 64.8% during the 1st quarter. Parallel Advisors LLC now owns 1,363 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 536 shares during the last quarter. 76.03% of the stock is owned by hedge funds and other institutional investors.
About Viking Therapeutics
(
Get Free Report)
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Viking Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.
While Viking Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
